Cargando…

Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells

Background: Therapeutic options for CD19(+) relapses after anti-CD19 CAR-T cells are still debated; second infusion of anti-CD19 CAR-T cells, therapeutic antibodies, or targeted therapies can be discussed. Here, we explore the immunophenotyping and lysis sensitivity of CD19(+) ALL relapse after anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grain, Audrey, Ollier, Jocelyn, Guillaume, Thierry, Chevallier, Patrice, Le Calvez, Baptiste, Eveillard, Marion, Clémenceau, Béatrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953531/ https://www.ncbi.nlm.nih.gov/pubmed/36830882 http://dx.doi.org/10.3390/biomedicines11020345

Ejemplares similares

Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
por: Wang, Jia, et al.
Publicado: (2020)

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
por: Gu, Runxia, et al.
Publicado: (2020)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
por: Jacoby, Elad, et al.
Publicado: (2016)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
por: Xu, Xinjie, et al.
Publicado: (2019)

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
por: Wullenkord, Ramona, et al.
Publicado: (2020)

Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report
por: Htun, Kyaw Thu, et al.
Publicado: (2021)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
por: Yang, Fei, et al.
Publicado: (2019)

Sars-Cov-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Transplant Recipients
por: Clemenceau, Beatrice, et al.
Publicado: (2022)

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
por: Zhang, Li-Na, et al.
Publicado: (2018)

Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity
por: Zhang, Na, et al.
Publicado: (2022)

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
por: Liu, Sining, et al.
Publicado: (2023)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
por: Jullien, Maxime, et al.
Publicado: (2022)

A report on Lineage switch at relapse of CD19 CAR-T therapy for Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
por: Li, Lan-Zhu, et al.
Publicado: (2020)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers
por: Blanco, Belén, et al.
Publicado: (2022)

Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
por: Zhang, Cheng, et al.
Publicado: (2020)

Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
por: Lamble, Adam J., et al.
Publicado: (2022)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
por: Boissel, Nicolas, et al.
Publicado: (2023)

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
por: Nie, Yuru, et al.
Publicado: (2020)

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
por: Cordoba, Shaun, et al.
Publicado: (2021)

Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
por: Reinert, Jochim, et al.
Publicado: (2021)

S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY
por: Roddie, Claire, et al.
Publicado: (2023)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: LI, Tingting, et al.
Publicado: (2023)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2020)

CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia
por: Zebley, Caitlin C., et al.
Publicado: (2021)

Successful treatment of acute B lymphoblastic leukemia relapse in the skin and testicle by anti-CD19 CAR-T with IL-6 knocking down: a case report
por: Liu, Ze-Fa, et al.
Publicado: (2020)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Marrow relapse on maintenance chemotherapy in childhood acute lymphoblastic leukaemia.
por: Kearney, P. J., et al.
Publicado: (1979)

Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy
por: Le Calvez, Baptiste, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i79rni9elr57ibspuggkcuc5dh